Millennium Management LLC recently announced the acquisition of new stake in Affimed N.V. (NASDAQ:AFMD). The institutional investor has increased its shareholding in the Healthcare company by 125.28% to 5.03 million shares with purchase of 2.8 million shares. This fresh investment now brings its stake to 6.59% valued currently at $17.74 million. In addition, BlackRock Fund Advisors raised its holdings by 0.15 million to 4.18 million shares. And 683 Capital Management LLC has lifted its position by 143.33% or 2.15 million shares – to 3.65 million shares.
With over 1.11 million Affimed N.V. (AFMD) shares trading Monday and a closing price of $3.65 on the day, the dollar volume was approximately $4.07 million. The shares have shown a positive weekly performance of 1.39% and its price on 08/24/20 lost nearly -4.70%. Currently, there are 79.19M common shares owned by the public and among those 68.61M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 5 analysts who have offered their price forecasts for AFMD have a consensus price objective of $6.11. The analysts have set the share’s price value over the next 12 months at a high of $8.50 and a low of $5.07 should the stock experience a downside. Incidentally, analysts’ outlook for the Affimed N.V. stock is 1.60 for the next 12 months. But an upside of 57.06% will see the stock hit the forecast high price target while mean target price for the stock is $5.10.
The top 3 mutual fund holders in Affimed N.V. are iShares Russell 2000 ETF, iShares NASDAQ Biotechnology ETF, and iShares Russell 2000 Growth ETF. iShares Russell 2000 ETF owns 1.56 million shares of the company’s stock, all valued at over $5.51 million. The company sold 73066.0 shares recently to bring their total holdings to about 2.05% of the shares outstanding. iShares NASDAQ Biotechnology ETF sold 6050.0 shares to see its total holdings shrink to 0.78 million shares valued at over $2.77 million and representing 1.03% of the shares outstanding. iShares Russell 2000 Growth ETF sold 6648.0 shares to bring its total holdings to over 0.68 million shares at a value of $2.39 million. iShares Russell 2000 Growth ETF now owns shares totaling to 0.89% of the shares outstanding.
Shares of Affimed N.V. (NASDAQ: AFMD) opened at $3.89, up $0.06 from a prior closing price of $3.83. However, the script later closed the day at $3.65, down -4.70%. The company’s stock has a 5-day price change of 1.39% and 17.36% over the past three months. AFMD shares are trading 33.21% year to date (YTD), with the 12-month market performance up to 36.19% higher. It has a 12-month low price of $1.42 and touched a high of $4.91 over the same period. Currently, 1.11 million shares have been traded, compared to an average intraday trading volume of 1.53 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.47%, -9.03%, and 28.38% respectively.
Institutional ownership of Affimed N.V. (NASDAQ: AFMD) shares accounts for 54.20% of the company’s 79.19M shares outstanding. Mutual fund holders own 12.97%, while other institutional holders and individual stakeholders account for 43.60% and — respectively.
It has a market capitalization of $347.48M and a beta (3y monthly) value of 2.56. The earnings-per-share (ttm) stands at -$0.74. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.29% over the week and 7.57% over the month.
Analysts forecast that Affimed N.V. (AFMD) will achieve an EPS of -$0.1 for the current quarter, -$0.12 for the next quarter and -$0.3 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.17 while analysts give the company a high EPS estimate of -$0.04. Comparatively, EPS for the current quarter was -$0.19 a year ago. Earnings per share for the fiscal year are expected to decrease by -56.50%, and 41.20% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 5 brokerage firm advisors rate Affimed N.V. (AFMD) as a “Strong Buy” at a consensus score of 1.60. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 0 of the 5 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AFMD, a number of firms have released research notes about the stock. SVB Leerink stated their Outperform rating for the stock in a research note on March 28, 2019, with the firm’s price target at. Jefferies coverage for the Affimed N.V. (AFMD) stock in a research note released on August 28, 2018 offered a Buy rating with a price target of. SunTrust was of a view on July 14, 2017 that the stock is Buy, while Leerink Partners gave the stock Mkt Perform rating on August 12, 2016, issuing a price target of. Leerink Partners on their part issued Mkt Perform rating on May 19, 2016.